A Single-center, Open-label, Single-dose, Randomized, 3-way Crossover Phase 1 Study in Healthy Adult Participants to Assess the Relative Oral Bioavailability of Macitentan 75 mg as Two Different Test Formulations Compared to the Reference Formulation
Latest Information Update: 01 Mar 2024
At a glance
- Drugs Macitentan (Primary)
- Indications Congenital heart defects; Eisenmenger complex; Heart failure; Pulmonary arterial hypertension; Pulmonary hypertension
- Focus Pharmacokinetics
- Sponsors Actelion Pharmaceuticals
Most Recent Events
- 08 Nov 2022 Status changed from recruiting to completed.
- 13 Sep 2022 Planned End Date changed from 21 Aug 2022 to 16 Sep 2022.
- 05 Jul 2022 Status changed from not yet recruiting to recruiting.